{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:25:24Z","timestamp":1726446324215},"edition-number":"0","reference-count":1,"publisher":"CRC Press","isbn-type":[{"type":"electronic","value":"9780429214943"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,6]]},"DOI":"10.3109\/9780203012055-27","type":"book-chapter","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:51:47Z","timestamp":1362444707000},"page":"389-402","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetics and pharmacogenomics in multiple sclerosis"],"prefix":"10.3109","member":"301","reference":[{"key":"ref21","unstructured":"1. Lesko LJ, Salerno RA, Spear BB, et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDAPWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003; 43: 342\u201358 2. Martin R, Leppert D. A plea for \u2018omics research in complex diseases such as multiple sclerosis \u2013 a change of mind is needed. J Neurol Sci 2004; 222: 3\u20135 3. Roses A. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev Drug Discov 2002; 1: 541\u20139 4. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954; 70: 266\u201373 5. Evans DA, Clarke CA. Pharmacogenetics. Br Med Bull 1961; 17: 234\u201340 6. Porter IH. Genetic basis of drug metabolism in man. Toxicol Appl Pharmacol 1964; 6: 499\u2013511 7. Barcellos LF, Oksenberg JR, Green AJ, et al. Multiple Sclerosis Genetics Group. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; 125: 150\u20138 8. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579\u201382 9. Fazekas F, Strasser-Fuchs S, Kolegger H, et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853\u20137 10. Fusco C, Andreone V, Coppola G, et al. HLADRB1*1501 and response to copolymer-1 therapy in relapsing\u2013remitting multiple sclerosis. Neurology 2001; 57: 1976\u20139 11. Villoslada P, Barcellos LF, Rio J, et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-\u03b2. J Neuroimmunol 2002; 130: 194\u2013201 12. Sriram U, Barcellos LF, Villoslada P, et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003; 4: 147\u201352 13. Leyva L, Fernandez O, Fedetz M, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005; 163: 165\u201371 14. Mart\u00ednez A, de las Heras V, Mas Fontao A, et al. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol 2006; 173: 196\u20139 15. Wergeland S, Beiske A, Nyland H, et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005; 12: 171\u20135 16. Becker KG, Mattson DH, Powers JM, et al. Analysis of a sequenced cDNA library from multiple sclerosis lesions. J Neuroimmunol 1997; 77: 27\u201338 17. Whitney LW, Becker KG, Tresser NJ, et al. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann Neurol 1999; 46: 425\u20138 18. Baranzini SE, Elfstrom C, Chang SY, et al. Transcriptional analysis of multiple sclerosis brain lesions"}],"container-title":["Multiple Sclerosis Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.crcnetbase.com\/doi\/pdf\/10.3109\/9780203012055-27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T17:48:54Z","timestamp":1608745734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.taylorfrancis.com\/books\/9780203012055\/chapters\/10.3109\/9780203012055-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,6]]},"ISBN":["9780429214943"],"references-count":1,"URL":"https:\/\/doi.org\/10.3109\/9780203012055-27","relation":{},"subject":[],"published":{"date-parts":[[2007,3,6]]}}}